← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

GRAIL, Inc. (GRAL) 10-Year Financial Performance & Capital Metrics

GRAL • • Industrial / General
HealthcareDiagnostics & ResearchCancer Diagnostics & Oncology TestingLiquid Biopsy & Circulating Tumor DNA
AboutGRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.Show more
  • Revenue $126M +34.9%
  • EBITDA -$2.03B -49.7%
  • Net Income -$2.03B -38.3%
  • EPS (Diluted) -63.54 -34.6%
  • Gross Margin -62.12% +39.5%
  • EBITDA Margin -1617.18% -11.0%
  • Operating Margin -1743.03% -7.1%
  • Net Margin -1613.92% -2.5%
  • ROE -65.92% -86.5%
  • ROIC -54.81% -96.1%
  • Debt/Equity 0.03 +17.6%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 96 (top 4%)
  • ✓Trading at only 1.2x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y104.84%
TTM20.53%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM79.01%

EPS CAGR

10Y-
5Y-
3Y-
TTM81.31%

ROCE

10Y Avg-47%
5Y Avg-47.92%
3Y Avg-54.26%
Latest-59.98%

Peer Comparison

Liquid Biopsy & Circulating Tumor DNA
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
BIAFbioAffinity Technologies, Inc.6.39M1.42-0.06269.75%-217.5%-165.57%0.58
VNRXVolitionRx Limited35.61M0.29-0.9459.1%-15.54%
BDSXBiodesix, Inc.66.27M8.33-1.2645.3%-49.31%-337.3%2.97
GRALGRAIL, Inc.3.8B97.44-1.5334.9%-286.43%-18.14%0.03
GHGuardant Health, Inc.14.54B111.98-31.4631.04%-44.18%-45.84%
ADVBAdvanced Biomed Inc. Common Stock6.86M0.32-67.45-135.32%-77.48%0.00

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+00014.61M55.55M93.11M125.59M
Revenue Growth %----2.8%0.68%0.35%
Cost of Goods Sold+000114.61M172M188.72M203.62M
COGS % of Revenue---7.84%3.1%2.03%1.62%
Gross Profit+000-100M-116.45M-95.61M-78.02M
Gross Margin %----6.84%-2.1%-1.03%-0.62%
Gross Profit Growth %-----0.16%0.18%0.18%
Operating Expenses+287.5M255.66M316.42M1.17B5.33B1.42B2.11B
OpEx % of Revenue---79.75%95.89%15.25%16.81%
Selling, General & Admin64.34M88.58M123.51M234.06M296.44M362.56M367.82M
SG&A % of Revenue---16.02%5.34%3.89%2.93%
Research & Development223.16M167.09M192.91M460.21M329.58M338.75M322.38M
R&D % of Revenue---31.5%5.93%3.64%2.57%
Other Operating Expenses000471.07M4.7B718.47M1.42B
Operating Income+-287.5M-255.66M-316.42M-1.27B-5.44B-1.52B-2.19B
Operating Margin %----86.6%-97.98%-16.28%-17.43%
Operating Income Growth %-0.11%-0.24%-3%-3.3%0.72%-0.44%
EBITDA+-273.42M-245.36M-308.85M-1.21B-5.29B-1.36B-2.03B
EBITDA Margin %----82.6%-95.2%-14.57%-16.17%
EBITDA Growth %-0.1%-0.26%-2.91%-3.38%0.74%-0.5%
D&A (Non-Cash Add-back)14.08M10.31M7.56M58.45M154.76M158.7M158.06M
EBIT-283.5M-253.44M-316.3M-1.27B-742.46M-796.92M-768.22M
Net Interest Income+8.34M12.43M6.14M332K1.74M7.95M26.73M
Interest Income8.34M12.43M6.14M332K1.74M7.95M26.73M
Interest Expense0000000
Other Income/Expense12.26M10.61M4.29M90K1.5M7.75M26.8M
Pretax Income+-275.23M-245.05M-312.12M-1.27B-5.44B-1.51B-2.16B
Pretax Margin %----86.59%-97.95%-16.19%-17.22%
Income Tax+485K-195K33K-17.48M-42.29M-41.95M-135.36M
Effective Tax Rate %1%1%1%0.99%0.99%0.97%0.94%
Net Income+-275.72M-244.85M-312.16M-1.25B-5.4B-1.47B-2.03B
Net Margin %----85.39%-97.19%-15.74%-16.14%
Net Income Growth %-0.11%-0.27%-3%-3.33%0.73%-0.38%
Net Income (Continuing)-275.72M-244.85M-312.16M-1.25B-5.4B-1.47B-2.03B
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-2.42-1.99-2.52-40.18-173.87-47.20-63.54
EPS Growth %-0.18%-0.27%-14.94%-3.33%0.73%-0.35%
EPS (Basic)-2.42-1.99-2.52-40.18-173.87-47.20-63.54
Diluted Shares Outstanding114.14M123.19M123.67M31.05M31.05M31.05M31.9M
Basic Shares Outstanding114.14M123.19M123.67M31.05M31.05M31.05M31.9M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+649.23M557.51M595.92M242.73M295.63M156.06M819.86M
Cash & Short-Term Investments641.35M544.34M583.48M221.16M241.6M97.29M763.47M
Cash Only95.09M143.19M170.19M221.16M241.6M97.29M214.23M
Short-Term Investments546.26M401.15M413.29M000549.24M
Accounts Receivable0006.88M18.61M22.35M24.64M
Days Sales Outstanding---171.91122.3187.6371.61
Inventory000019.75M21.7M18.63M
Days Inventory Outstanding----41.9241.9633.4
Other Current Assets0006.89M000
Total Non-Current Assets+37.61M78.01M110.38M9.5B5.31B4.4B2.16B
Property, Plant & Equipment33.04M59.46M101.39M216.37M198.72M169.38M135.43M
Fixed Asset Turnover---0.07x0.28x0.55x0.93x
Goodwill0006.2B1.5B888.94M0
Intangible Assets0003.07B2.94B2.69B2.02B
Long-Term Investments1.63M15.16M2.05M04.53M4.22M0
Other Non-Current Assets2.94M3.38M6.94M7.1M6.14M7.98M11.12M
Total Assets+686.85M635.52M706.3M9.74B5.6B4.56B2.98B
Asset Turnover---0.00x0.01x0.02x0.04x
Asset Growth %--0.07%0.11%12.79%-0.42%-0.19%-0.35%
Total Current Liabilities+74.16M44.93M83.97M97.89M134.94M163.61M76.92M
Accounts Payable12.75M6.09M24.51M17.65M17.48M19.67M4.84M
Days Payables Outstanding---56.237.138.058.68
Short-Term Debt000013.34M14.81M0
Deferred Revenue (Current)0000001000K
Other Current Liabilities267K23K12.41M4.51M65.96M87.64M22.69M
Current Ratio8.75x12.41x7.10x2.48x2.19x0.95x10.66x
Quick Ratio8.75x12.41x7.10x2.48x2.04x0.82x10.42x
Cash Conversion Cycle----127.1491.5496.33
Total Non-Current Liabilities+12.32M40.06M60.49M209.51M821M747.13M402.98M
Long-Term Debt0000000
Capital Lease Obligations800K36.64M57.54M96.75M82.67M69.6M54.88M
Deferred Tax Liabilities0000735.19M676.03M345.86M
Other Non-Current Liabilities11.52M3.42M2.95M112.76M3.13M1.5M2.24M
Total Liabilities86.47M84.99M144.46M307.4M955.94M910.74M479.9M
Total Debt+2.52M42.04M62.99M110.56M96.01M84.41M68.14M
Net Debt-92.57M-101.15M-107.21M-110.6M-145.59M-12.88M-146.09M
Debt / Equity0.00x0.08x0.11x0.01x0.02x0.02x0.03x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage-------
Total Equity+600.37M550.53M561.84M9.43B4.65B3.65B2.5B
Equity Growth %--0.08%0.02%15.79%-0.51%-0.22%-0.31%
Book Value per Share5.264.474.54303.69149.62117.4278.47
Total Shareholders' Equity600.37M550.53M561.84M9.43B4.65B3.65B2.5B
Common Stock129K138K151K10.34B10.96B11.42B34K
Retained Earnings-1.06B-1.31B-1.62B-911.54M-6.31B-7.78B-9.8B
Treasury Stock0000000
Accumulated OCI128K2.46M3.6M315K894K1.07M1.45M
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-209.26M-245.79M-232M-688.13M-561.31M-595.8M-577.16M
Operating CF Margin %----47.09%-10.1%-6.4%-4.6%
Operating CF Growth %--0.17%0.06%-1.97%0.18%-0.06%0.03%
Net Income-275.72M-244.85M-312.16M-1.25B-5.4B-1.47B-2.03B
Depreciation & Amortization14.08M10.31M7.56M58.45M154.76M158.7M158.06M
Stock-Based Compensation11.04M28.39M45.99M681.91M75.73M97.23M86.08M
Deferred Taxes0000-39.06M-38.15M-134.25M
Other Non-Cash Items1.66M-353K9.38M-201M4.66B644.38M1.36B
Working Capital Changes39.67M-39.28M17.22M20.29M-14.46M7.72M-24.28M
Change in Receivables000-6.88M-8.68M-1.38M-3.37M
Change in Inventory000-5.67M-14.08M-1.94M3.07M
Change in Payables-338K-6.55M002.34M2.89M-14.63M
Cash from Investing+-93.39M133.04M-12.79M344.81M-22.86M-12.89M-551.01M
Capital Expenditures-15.99M-3.33M-11.9M-69.93M-22.86M-12.89M-5.21M
CapEx % of Revenue---4.79%0.41%0.14%0.04%
Acquisitions-------
Investments-------
Other Investing-77.4M136.37M-885K414.74M000
Cash from Financing+300.62M160.33M275.11M394.74M604.82M463.77M1.24B
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid0000000
Share Repurchases-------
Other Financing302.13M161.88M275.92M388.93M604.82M463.77M1.24B
Net Change in Cash-------
Free Cash Flow+-225.25M-249.13M-243.91M-758.06M-584.17M-608.69M-582.36M
FCF Margin %----51.88%-10.52%-6.54%-4.64%
FCF Growth %--0.11%0.02%-2.11%0.23%-0.04%0.04%
FCF per Share-1.97-2.02-1.97-24.41-18.81-19.60-18.26
FCF Conversion (FCF/Net Income)0.76x1.00x0.74x0.55x0.10x0.41x0.28x
Interest Paid0000000
Taxes Paid0000000

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)-45.92%-42.55%-56.12%-24.97%-76.71%-35.35%-65.92%
Return on Invested Capital (ROIC)-42.46%-40.06%-52.5%-19.42%-59.07%-27.95%-54.81%
Gross Margin----684.39%-209.63%-102.69%-62.12%
Net Margin----8539.39%-9719.35%-1574.23%-1613.92%
Debt / Equity0.00x0.08x0.11x0.01x0.02x0.02x0.03x
FCF Conversion0.76x1.00x0.74x0.55x0.10x0.41x0.28x
Revenue Growth----280.17%67.61%34.9%

Revenue by Geography

2024
Americas108.54M
Americas Growth-
Non-US14.69M
Non-US Growth-

Frequently Asked Questions

Growth & Financials

GRAIL, Inc. (GRAL) reported $141.8M in revenue for fiscal year 2024.

GRAIL, Inc. (GRAL) grew revenue by 34.9% over the past year. This is strong growth.

GRAIL, Inc. (GRAL) reported a net loss of $406.2M for fiscal year 2024.

Dividend & Returns

GRAIL, Inc. (GRAL) has a return on equity (ROE) of -65.9%. Negative ROE indicates the company is unprofitable.

GRAIL, Inc. (GRAL) had negative free cash flow of $329.8M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.